Low-dose intranasal PT-141 combined with sildenafil produced synergistic erectile effects in ED patients — combining brain-acting (desire) with peripheral-acting (blood flow) mechanisms for superior results.
Key findingCo-administration of low-dose intranasal PT-141 (melanocortin agonist) with sildenafil (PDE5 inhibitor) produced synergistic erectile responses in ED
What the researchers found
Co-administration of low-dose intranasal PT-141 (melanocortin agonist) with sildenafil (PDE5 inhibitor) produced synergistic erectile responses in ED patients — combining central desire/arousal with peripheral vasodilation for superior outcomes.
Why it matters
Relevant for pt-141, sexual-health, clinical-trials.
How the study worked
RCT study on pt-141, sexual-health.
What this study cannot tell us
See abstract.
How to read the evidence
moderate evidence.
When this study was published
Published in 2005.
The bigger picture
Advances peptide research with clinical implications.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.
Urology, 65(4), 755-9
Citation
Diamond, L E; Earle, D C; Garcia, W D; Spana, C. (2005). Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.. Urology, 65(4), 755-9.